Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 3 Late Lumen Loss of Vestasync Stent Versus the FDA-Approved DES
Late loss results reported for the Food and Drug Administration (FDA)–approved drug-eluting stent (DES) in contrast to the findings of the current analysis. When compared to the published results of other DES tested in similar scenarios, the in-stent late loss of the Vestasync stent is equivalent to that of the Endeavor and Taxus stents and slightly higher than that of the Cypher and Xience/Promus stents. *Invasive follow-up done at 4 months. **Invasive follow-up done at 6 months. FIM = first-in-man; SPIRIT = Stroke Prevention in Reversible Ischemia Trial.
|
